Kazunori Kawazoe (Kazunori Kawasoe)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Immune Response

Cell Proliferation

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Tatsuro Watanabe, Yuta Yamamoto, Yuki Kurahashi, Kazunori Kawazoe, Keisuke Kidoguch, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Hideaki Nakamura, Seiji Okada, Eisaburo Sueoka, Shinya Kimura
Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells. Blood advances (2024)
Tatsuro Watanabe, Yuta Yamamoto, Yuki Kurahashi, Kazunori Kawazoe, Keisuke Kidoguch, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Hideaki Nakamura, Seiji Okada, Eisaburo Sueoka, Shinya Kimura
Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells. Blood advances 8 (6) (2024)
Tatsuro Watanabe, Yuta Yamamoto, Yuki Kurahashi, Kazunori Kawazoe, Keisuke Kidoguch, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Hideaki Nakamura, Seiji Okada, Eisaburo Sueoka, Shinya Kimura
Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells. Blood advances 8 (6) (2024)
Kazuharu Kamachi, Hiroshi Ureshino, Tatsuro Watanabe, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Kazunori Kawazoe, Toshimi Hoshiko, Yuta Yamamoto, Yuki Kurahashi, Shinya Kimura
Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia. Cancer research communications 3 (2) (2023)
Kazuharu Kamachi, Hiroshi Ureshino, Tatsuro Watanabe, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Kazunori Kawazoe, Toshimi Hoshiko, Yuta Yamamoto, Yuki Kurahashi, Shinya Kimura
Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia. Cancer research communications 3 (2) (2023)